A Biomimicking and Multiarm Self-Indicating Nanoassembly for Site-Specific Photothermal-Potentiated Thrombolysis Assessed in Microfluidic and in vivo Models

Thrombolytic and antithrombotic therapies are limited by short circulation time and the risk of off-target hemorrhage. We propose integrating a thrombus-homing strategy with photothermal therapy to address these limitations. Using glycol chitosan, polypyrrole, iron oxide and heparin, we developed bi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced healthcare materials 2023-09, Vol.12 (24), p.e2300682-e2300682
Hauptverfasser: Liu, Kuan-Ting, Quiñones, Edgar Daniel, Liu, Ming-Hsin, Lin, Che-Wei, Chen, Yan-Ting, Chiang, Chia-Che, Wu, Kevin Chia-Wen, Fan, Yu-Jui, Chuang, Er-Yuan, Yu, Jiashing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Thrombolytic and antithrombotic therapies are limited by short circulation time and the risk of off-target hemorrhage. We propose integrating a thrombus-homing strategy with photothermal therapy to address these limitations. Using glycol chitosan, polypyrrole, iron oxide and heparin, we developed biomimicking GCPIH nanoparticles for targeted thrombus delivery and thrombolysis. The nanoassembly achieved precise delivery of polypyrrole, exhibiting biocompatibility, selective accumulation at multiple thrombus sites, and enhanced thrombolysis through photothermal activation. To simulate targeted thrombolysis, we designed a microfluidic model predicting thrombolysis dynamics in realistic pathological scenarios. Human blood assessments validated the precise homing of GCPIH nanoparticles to activated thrombus microenvironments. Efficient near-infrared phototherapeutic effects were demonstrated at thrombus lesions under physiological flow conditions ex vivo. Our combined investigations provide compelling evidence supporting the potential of GCPIH nanoparticles for effective thrombus therapy. The microfluidic model also offers a platform for advanced thrombolytic nanomedicine development. This article is protected by copyright. All rights reserved.
ISSN:2192-2640
2192-2659
DOI:10.1002/adhm.202300682